EBV Vaccines in the Prevention and Treatment of Nasopharyngeal Carcinoma

EBV Vaccines in the Prevention and Treatment of Nasopharyngeal Carcinoma

Epstein–Barr virus (EBV), a ubiquitous human herpesvirus, has been robustly linked to the pathogenesis of nasopharyngeal carcinoma (NPC). The mechanism of EBV-induced NPC involves complex interactions between viral proteins and host cell pathways. This review aims to comprehensively outline the mech...

Full description

Saved in:

Bibliographic Details
Main Authors:	Weiwei Zhang, Chuang Wang, Yousheng Meng, Lang He, Mingqing Dong
Format:	Article
Language:	English
Published:	MDPI AG 2025-04-01
Series:	Vaccines
Subjects:	Epstein–Barr virus nasopharyngeal carcinoma vaccines prevent treatment
Online Access:	https://www.mdpi.com/2076-393X/13/5/478
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prognostic implications of EBER and EBV DNA combinations in nasopharyngeal carcinoma in endemic areas
by: Ying Li, et al.
Published: (2025-08-01)

Screening for nasopharyngeal carcinoma in high-incidence regions——Next steps
by: Allan Hildesheim
Published: (2024-09-01)

Exploring the interplay between EBV and autophagy-related gene expression patterns in nasopharyngeal carcinoma
by: Abdullah E. Alanazi, et al.
Published: (2025-06-01)

Monitoring the efficacy of conservative treatment of nasopharyngeal carcinoma by examining Epstein–Barr virus DNA titers in blood plasma (review)
by: D. A. Miroshnichenko, et al.
Published: (2020-11-01)

Advancements in the epidemiology of nasopharyngeal carcinoma
by: DU Yun, et al.
Published: (2024-09-01)

Diagnostic performance of EBV DNA load testing for nasopharyngeal carcinoma in nasopharyngeal swab outperforms the approach in other specimens
by: Xue-Qi Li, et al.
Published: (2025-07-01)

A nomogram integrating clinical stage and pre-EBV DNA to identify the cycles of induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma
by: Sunqin Cai, et al.
Published: (2025-06-01)

Molecular diagnosis of nasopharyngeal carcinoma: Past and future
by: Cheng-Lung Hsu, et al.
Published: (2025-02-01)

Re-searching nasopharyngeal carcinoma
by: Ingemar Ernberg, et al.
Published: (2024-09-01)

The burden and outcome of nasopharyngeal carcinoma in Sweden
by: Evelina Gille, et al.
Published: (2025-07-01)

The abnormally high expression of RAB11A promotes the invasion of nasopharyngeal carcinoma
by: ZHOU Lu, et al.
Published: (2025-02-01)

Early diagnosis and personalized comprehensive treatment of nasopharyngeal carcinoma based on Epstein-Barr virus-specific markers
by: CHEN Jie, et al.
Published: (2024-09-01)

Epidemiology and treatment outcome of nasopharyngeal carcinoma in a low-incidence population – a DAHANCA analysis in Denmark 2000–2018
by: Erik Schiess, et al.
Published: (2024-11-01)

A Canadian Perspective on Systemic Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma
by: Anna Spreafico, et al.
Published: (2025-01-01)

Epstein-Barr virus mRNA vaccine synergizes with NK cells to enhance nasopharyngeal carcinoma eradication in humanized mice
by: Kun Huang, et al.
Published: (2025-06-01)

Integrated Early CRP Kinetics and Plasma EBV DNA Clearance as Prognostic Biomarkers in De Novo Metastatic Nasopharyngeal Carcinoma Treated with First-Line Chemoimmunotherapy
by: Fang M, et al.
Published: (2025-05-01)

CRISPR/Cas13-Mediated Inhibition of EBNA1 for Suppression of Epstein–Barr Virus Transcripts and DNA Load in Nasopharyngeal Carcinoma Cells
by: Lin Lin, et al.
Published: (2025-06-01)

Targeting the LMP1‐ALIX axis in EBV+ nasopharyngeal carcinoma inhibits immunosuppressive small extracellular vesicle secretion and boosts anti‐tumor immunity
by: Fajian He, et al.
Published: (2024-12-01)

ebv-sisRNA-3 contributes to the formation of G4-associated R-loop upstream of EBV lytic replication origin in latently infected cells
by: Bo Wang, et al.
Published: (2025-06-01)

A Nomogram Based on Tumor Response to Induction Chemotherapy and Plasma Epstein–Barr Virus DNA Level after Induction Chemotherapy to Explore Individualized Treatment of Patients with Locally Advanced Nasopharyngeal Carcinoma
by: Liu F, et al.
Published: (2025-03-01)

The prognostic value of boost dose in residual cervical lymph nodes in nasopharyngeal carcinoma patients after intensity-modulated radiotherapy: a retrospective study
by: Mengting Xu, et al.
Published: (2025-02-01)

Synchronous primary parotid tuberculosis and EBV-associated primary lymphoepithelial carcinoma
by: Anandhi Anbalagan, et al.
Published: (2025-04-01)

Challenges in diagnosing nasopharyngeal tumors
by: Alexandru Aristide Alexe, et al.
Published: (2024-10-01)

Diagnostic significance of DNA and antibodies against capsid antigens of anti-Epstein–Barr virus antibodies levels in blood plasma of nasopharyngeal carcinoma patients from non-endemic region
by: V. E. Gurtsevich, et al.
Published: (2015-06-01)

Epstein-Barr virus (EBV) DNAemia in saliva of viral encephalitis and nasopharyngeal carcinoma patients
by: Nanditha Srinivasan, et al.
Published: (2025-01-01)

HLA II genes distribution in Epstein–Barr virus-associated nasopharyngeal carcinoma and other tumors of the oral cavity patients in Russia
by: N. B. Senyuta, et al.
Published: (2018-05-01)

First Indonesian Nasopharyngeal Cancer Whole Epigenome Sequencing Identify Tumour Suppressor CpG Methylation
by: Handoko, et al.
Published: (2025-01-01)

Specific Immune Responses and Oncolytic Effects Induced by EBV LMP2A-Armed Modified Ankara-Vaccinia Virus Vectored Vaccines in Nasopharyngeal Cancer
by: Liying Sun, et al.
Published: (2025-01-01)

A Liposome-Based Nanoparticle Vaccine Induces Effective Immunity Against EBV Infection
by: Ping Li, et al.
Published: (2025-03-01)

Recent Progress in the Vaccine Development Against Epstein–Barr Virus
by: Yihao Dai, et al.
Published: (2025-06-01)

Immunological Prevalence of EBV in Rheumatoid Arthritis Iraqi Patients
by: Wafaa Ayad Al-Nuaimy, et al.
Published: (2025-07-01)

Immunotherapy combined with chemotherapy without locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: two case reports and a literature review
by: Yingna Gao, et al.
Published: (2025-01-01)

Active EBV infection in children: associations between DNA load, infection status, immune status, and disease severity
by: Haipeng Yan, et al.
Published: (2025-04-01)

The role of EBV lytic genes in tumor development and progression
by: DENG Yizhang, et al.
Published: (2024-09-01)

[Translated article] An Update on EBV-related Cutaneous Lymphoproliferative Disorders: a Systematic Review
by: S. García-González, et al.
Published: (2025-04-01)

Acute hepatitis: a rare complication of Epstein-Barr virus (EBV) infection
by: Mehmet Uluğ, et al.
Published: (2010-10-01)

Histopathological characteristics of Epstein-Barr virus (EBV)–associated encephalitis and colitis in chronic active EBV infection
by: Betty A Kasimo, et al.
Published: (2025-05-01)

IN VITRO EFFECTS OF MEVASTATIN AND BIOLOGICAL PREPARATIONS UPON ACTIVATION OF EBV-SPECIFIC CD4+T LYMPHOCYTES FROM THE PATIENTS WITH RHEUMATOID ARTHRITIS
by: I. V. Shirinsky, et al.
Published: (2014-07-01)

Markers of Epstein–Barr virus in clinical assessment of Russian patients with nasopharyngeal cancer
by: K. V. Smirnova, et al.
Published: (2021-11-01)

In silico Approach of Some Selected Manuka Honey Constituents as Epstein–Barr Virus (EBV) Nuclear Antigen 1 (EBNA1) Inhibitors
by: Achmad Chusnu Romdhoni, et al.
Published: (2023-12-01)